Last edition
News about "anti-Epidermal Growth Factor Receptor"
Hutchmed Grants GSK Worldwide Rights to KRAS-EGFR Cancer Drug Candidate HMPL-A830
Hutchmed and GSK partner to advance HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumours.
Anti-Epidermal Growth Factor Receptor | 04/09/2026 | By News Bureau | 100
HUTCHMED Gains Wider NRDL Coverage and First Commercial Insurance Listing in China
Effective January 1, 2026, HUTCHMED will see expanded NRDL coverage for ELUNATE, ORPATHYS and SULANDA, while TAZVERIK has been added to China’s first National Commercial Health Insurance Innovative Drug List, marking its entry into commercial insurance coverage.
Anti-Epidermal Growth Factor Receptor | 08/12/2025 | By Dineshwori | 324
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy